PCAAVAN Stock Latest News
Private CompaniesAAVantgarde Bio Highlights Dual-AAV Programs Ahead of Healthcare Conference2d agoAAVAN
Private CompaniesAAVantgarde Bio Highlights Novel Endpoints and Gene Therapy Focus in Ophthalmology3d agoAAVAN
Private CompaniesAAVantgarde Bio Supports Usher Syndrome Patient-Input Initiative4d agoAAVAN
Private CompaniesAAVantgarde Bio Highlights Gene Therapy Focus at Ophthalmology Industry Event1M agoAAVAN- Private CompaniesEarly-Stage Gene Therapy Data Highlight Progress in Inherited Retinal Disease Programs1M agoAAVAN
Private CompaniesAAVantgarde Bio Highlights Pipeline Progress in Retinal Gene Therapy at EURetina 20262M agoAAVAN
Private CompaniesAAVantgarde Bio – Weekly Recap2M agoAAVAN
Private CompaniesGene Therapy Progress and Investor-Backed Visibility at AAVantgarde Bio2M agoAAVAN- Private CompaniesInvestor Spotlight on AAVantgarde Bio’s Gene Therapy Progress2M agoAAVAN
- Private CompaniesAAVantgarde Bio Strengthens Leadership with Senior Regulatory Hire2M agoAAVAN
Private CompaniesAAVantgarde Bio Highlights Scientific Role at Japanese Gene and Cell Therapy Meeting3M agoAAVANPrivate CompaniesAAVantgarde Bio Highlights Clinical Progress In Usher Syndrome Gene Therapy4M agoAAVAN
Private CompaniesAAVantgarde Bio Deepens Patient-Focused Strategy as Key Gene Therapy Readouts Approach4M agoAAVAN
Private CompaniesAAVantgarde Bio – Weekly Recap4M agoAAVAN- Private CompaniesDual-AAV Gene Therapy Programs Spotlighted at Dutch Bio Science Week4M agoAAVAN
Private CompaniesAAVantgarde Bio Builds Momentum in Retinal Gene Therapy as Early Clinical Data Near4M agoAAVAN